


**Amendments to the Claims**

Please cancel Claims 28, 32 and 34. Please amend Claims 3-21, 23, 25-27, 29-31 and 33. The Claim Listing below will replace all prior versions of the claims in the application:



**Claim Listing**

1. (Original) A compound of formula (1), or a pharmaceutically acceptable salt thereof:



wherein:

- Ar is a substituted heteroaryl group bearing at least one nitro or azido group or is a group of formula (2) or (3);



- $R_1$  is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl;
- $R_2$  is alkyl, alkoxy, thioalkoxy or halo;
- $R_3$ ,  $R_4$  and  $R_5$  are each independently alkyl, alkoxy, thioalkoxy or halo with the proviso that at least two of  $R_3$ ,  $R_4$  or  $R_5$  are alkoxy;

- L is -OC(O)- or -OP(O)(OR<sub>6</sub>)-;
  - n is 0 or 1;
  - X is O, S or NR<sub>7</sub>;
  - Y is hydrogen, alkyl, alkoxy, thioalkoxy, halo, hydroxy or dihydrogenphosphate;
  - R<sub>6</sub> is H or alkyl;
  - R<sub>7</sub> is H or alkyl;
  - R<sub>8</sub> is hydrogen, alkoxy or dialkylaminoalkyl;
  - R<sub>9</sub> is optionally substituted alkyl;
  - R<sub>10</sub> is hydrogen, alkyl, alkoxy or dialkylaminoalkyl;
  - R<sub>11</sub> and R<sub>12</sub> are independently hydrogen, alkyl, alkoxy, thioalkoxy, amino, alkylamino, dialkylamino, morpholino, alkylmorpholino, piperidino, alkylpiperidino, piperazino, alkylpiperazino or 1-aziridinyl; and
  - A, together with the carbon atoms to which it is fused, is an optionally substituted aryl or heteroaryl ring.
2. (Original) A compound according to claim 1, wherein the alkyl groups in the R<sub>1,7</sub> and R<sub>9,12</sub> substituents are unsubstituted or substituted with 1, 2 or 3 unsubstituted substituents chosen from halogen, amino, mono(C<sub>1</sub>-C<sub>4</sub> alkyl)amino, di(C<sub>1</sub>-C<sub>4</sub> alkyl)amino, hydroxy, C<sub>1</sub>-C<sub>4</sub> alkoxy and C<sub>1</sub>-C<sub>4</sub> alkylthio substituents.
3. (Currently amended) A compound according to ~~any one of the previous claims~~ claim 1, wherein the aryl and heteroaryl groups in the Ar, A and R<sub>1</sub> substituents are unsubstituted or substituted with 1, 2 or 3 unsubstituted substituents selected from halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, hydroxy, amino, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and C<sub>1</sub>-C<sub>4</sub> haloalkoxy.
4. (Currently amended) A compound according to ~~any one of the previous claims~~ claim 1, wherein R<sub>1</sub> is hydrogen, unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl, a phenyl group which is unsubstituted or substituted with 1, 2 or 3 unsubstituted substituents selected from halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, hydroxy, amino, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and C<sub>1</sub>-C<sub>4</sub> haloalkoxy or a heteroaryl group which is unsubstituted or substituted with 1, 2 or 3

unsubstituted substituents selected from halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, hydroxy, amino, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and C<sub>1</sub>-C<sub>4</sub> haloalkoxy substituents.

5. (Currently amended) A compound according to ~~any one of the previous claims~~ claim 1, wherein R<sub>1</sub> is hydrogen or unsubstituted C<sub>1</sub>-C<sub>2</sub> alkyl.
6. (Currently amended) A compound according to ~~any one of the previous claims~~ claim 1, wherein R<sub>2</sub> is unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl, unsubstituted C<sub>1</sub>-C<sub>4</sub> alkoxy, unsubstituted thio(C<sub>1</sub>-C<sub>4</sub> alkoxy) or a halo group.
7. (Currently amended) A compound according to ~~any one of the previous claims~~ claim 1, wherein R<sub>2</sub> is an unsubstituted C<sub>1</sub>-C<sub>2</sub> alkoxy group.
8. (Currently amended) A compound according to ~~any one of the previous claims~~ claim 1, wherein R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are the same or different and each represent unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl, unsubstituted C<sub>1</sub>-C<sub>4</sub> alkoxy, unsubstituted thio(C<sub>1</sub>-C<sub>4</sub> alkoxy) or a halo group provided that at least two of R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are alkoxy.
9. (Currently amended) A compound according to ~~any one of the previous claims~~ claim 1, wherein R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are the same or different and each represent unsubstituted C<sub>1</sub>-C<sub>2</sub> alkoxy.
10. (Currently amended) A compound according to ~~any one of the previous claims~~ claim 1, wherein X is O, S or NR<sub>7</sub>, wherein R<sub>7</sub> is hydrogen or unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl.
11. (Currently amended) A compound according to ~~any one of the previous claims~~ claim 1, wherein X is O, S or NH.
12. (Currently amended) A compound according to ~~any one of the previous claims~~ claim 1, wherein L is -OC(O)- or -OP(O)(OR<sub>6</sub>)-, wherein R<sub>6</sub> is hydrogen or unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl.

13. (Currently amended) A compound according to ~~any one of the previous claims~~ claim 1, wherein L is -OC(O)-.
14. (Currently amended) A compound according to ~~any one of claims 1 to 11~~ claim 1, wherein n is 0.
15. (Currently amended) A compound according to ~~any one of the previous claims~~ claim 1, wherein Y is selected from hydrogen, unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl, unsubstituted C<sub>1</sub>-C<sub>4</sub> alkoxy, unsubstituted thio(C<sub>1</sub>-C<sub>4</sub> alkoxy), halo, hydroxy and dihydrogenphosphate substituents.
16. (Currently amended) A compound according to ~~any one of the previous claims~~ claim 1, wherein Y is hydrogen.
17. (Currently amended) A compound according to ~~any one of the previous claims~~ claim 1, wherein Ar is a substituted aryl or 5 to 10 membered heteroaryl group which carries one substituent selected from a nitro or azido group and 0, 1 or 2 further unsubstituted substituents chosen from halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, hydroxy, amino, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and C<sub>1</sub>-C<sub>4</sub> haloalkoxy substituents.
18. (Currently amended) A compound according to ~~any one of the previous claims~~ claim 1, wherein Ar is an unsubstituted nitrophenyl, unsubstituted nitroimidazole, unsubstituted nitrothiophene or unsubstituted nitrofuranyl group.
19. (Currently amended) A compound according to ~~any one of claims 1 to 16~~ claim 1, wherein Ar is a group of formula (3), wherein R<sub>9</sub> is an unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl group.
20. (Currently amended) A compound according to ~~any one of claims~~ claim 19, wherein R<sub>9</sub> is an unsubstituted C<sub>1</sub>-C<sub>2</sub> alkyl group.
21. (Currently amended) A compound according to ~~any one of claims 1 to 16 and 19 to~~

- 20 claim 1, wherein R<sub>10</sub> is selected from hydrogen, unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl, unsubstituted C<sub>1</sub>-C<sub>4</sub> alkoxy and unsubstituted di(C<sub>1</sub>-C<sub>6</sub> alkyl)amino(C<sub>1</sub>-C<sub>6</sub> alkyl) substituents.
22. (Original) A compound according to claim 21, wherein R<sub>10</sub> is an unsubstituted C<sub>1</sub>-C<sub>2</sub> alkyl group.
23. (Currently amended) A compound according to ~~any one of claims 1 to 16 and 19 to 22~~ claim 1, wherein R<sub>11</sub> and R<sub>12</sub> are the same or different and each represent an unsubstituted substituent selected from hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, thio(C<sub>1</sub>-C<sub>4</sub> alkoxy), amino, (C<sub>1</sub>-C<sub>6</sub> alkyl)amino, di(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, morpholino, (C<sub>1</sub>-C<sub>6</sub> alkyl)morpholino, piperidino, (C<sub>1</sub>-C<sub>6</sub> alkyl)piperidino, piperazino, (C<sub>1</sub>-C<sub>6</sub> alkyl)piperazino and 1-aziridinyl substituents.
24. (Original) A compound according to claim 23, wherein R<sub>11</sub> and R<sub>12</sub> are the same or different and each represent a substituent selected from hydrogen, unsubstituted C<sub>1</sub>-C<sub>2</sub> alkoxy and unsubstituted (C<sub>1</sub>-C<sub>2</sub> alkyl)piperidino substituents.
25. (Currently amended) A compound according to ~~any one of the previous claims~~ claim 1 which is 1-(4-methoxy-3-(5-nitrothien-2-yl)methoxy)phenyl-2-(3,4,5-trimethoxy)phenyl-Z-ethene, 1-(4-Methoxy-3-(1-(5-nitrothien-2-yl)ethoxy))phenyl-2-(3,4,5-trimethoxy)phenyl-Z-ethene, 1-(4-Methoxy-3-(5-nitrothien-2-yl)methoxycarbonyloxy)phenyl-2-(3,4,5-trimethoxy)phenyl-Z-ethene, 5-Methoxy-3-((3,4,4',5-tetramethoxy-(Z)-stilbene-3'-yl)oxy)methyl-1,2-dimethylindole-4,7-dione or 3-((3,4,4',5-Tetramethoxy-(Z)-stilbene-3'-yl)oxy)methyl-1,2-dimethyl-5-(4-methylpiperazin-1-yl)indole-4,7-dione, or a pharmaceutically acceptable salt thereof.
26. (Currently amended) A pharmaceutical composition comprising a compound according to ~~any one of the previous claims~~ claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
27. (Currently amended) ~~A compound according to any one of claims 1 to 25;~~ A method

of ameliorating or reducing the incidence of a proliferative disorder in a patient, which method comprises administering to said patient an effective amount of a compound as defined in claim 1, or a pharmaceutically acceptable salt thereof, for use in the treatment of the human or animal body.

28. Canceled.
29. (Currently amended) ~~Use~~ A method according to claim ~~27~~ 28, wherein the proliferative disorder is cancer, rheumatoid arthritis, psoriatic lesions, diabetic retinopathy or wet age-related macular degeneration.
30. (Currently amended) ~~Use~~ A method according to claim ~~28 or 29~~ 27, wherein the proliferative disorder is a hypoxic disorder.
31. (Currently amended) ~~Use~~ A method according to ~~any one of claims 28 to 30~~ claim 27, wherein the medicament is for use in the prevention or treatment of a solid tumour or leukaemia.
32. Canceled.
33. (Currently amended) A method according to claim ~~32~~ 30, which method comprises administering to said patient an effective amount of:
  - (a) a compound as defined in ~~any one of claims 1 to 25~~ claim 1, or a pharmaceutically acceptable salt thereof; and
  - (b) a reductase, an anti-body reductase conjugate, a macromolecule-reductase conjugate or DNA encoding a reductase gene.
34. Canceled.